Navigation Links
Alios BioPharma initiates Phase 1 clinical trial for respiratory syncytial virus infection
Date:5/30/2013

SOUTH SAN FRANCISCO, CA May 30, 2013 Alios BioPharma, Inc. today announced that it has begun oral dosing of ALS-8176 in a Phase 1 clinical trial. ALS-8176 is a structurally novel, anti-respiratory syncytial virus (RSV) nucleoside analog that is being developed for the treatment of acute RSV infection. It is the only known nucleoside analog currently in clinical development for the treatment of RSV. ALS-8176 demonstrates potent anti-viral activity across multiple strains of RSV in preclinical studies and represents an important step forward in the development of more effective treatments for this serious and often life threatening disease.

The randomized, double-blind, placebo-controlled, Phase 1 study of orally administered ALS-8176 will evaluate safety, tolerability, and pharmacokinetics of single ascending doses and multiple ascending doses in healthy volunteers. The trial will assess several dose levels in up to 90 healthy adults.

ALS-8176 was discovered following the optimization of screening hits obtained through testing the Alios proprietary nucleoside analog library against replicating RSV in cell culture. The compound acts by blocking replication through a classic chain-termination mechanism and inhibits all RSV strains tested.

Due to their high barrier to viral resistance, nucleoside analogs have become the backbone of antiviral therapy in many clinical settings including the treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV) and herpes simplex virus (HSV). More recently, emerging data suggest the pivotal role nucleoside analogs will play in the future treatment of chronic hepatitis C (HCV).

"Alios believes ALS-8176 has great potential to become an effective first-line antiviral therapy for RSV infection, a disease where few treatment options currently exist," said Lawrence M. Blatt, PhD, Chief Executive Officer. "The advancement of ALS-8176 for RSV, together with the recently repo
'/>"/>

Contact: John Donovan
press@aliosbiopharma.com
650-635-5504
Alios BioPharma, Inc.
Source:Eurekalert

Page: 1 2

Related biology news :

1. Exclusive agreement to distribute Affinity Biosensors Archimedes system extends Malvern Instruments biopharma solutions
2. Discovery of a molecule that initiates maturation of mammalian eggs can lead to more IVF pregnancies
3. Carnegie Mellon neuroscientists discover new phase of synaptic development
4. Monoclonal Antibody with Xencors High ADCC Fc Technology Enters Phase 2 Study in B-cell Acute Lymphoblastic Leukemia
5. FDA approves Phase II of stem cell trial for ALS led by U-Ms Dr. Eva Feldman
6. In beef production, cow-calf phase contributes most greenhouse gases
7. F1000Research, the first Open Science publisher, launches following a successful beta testing phase
8. National Geographic unveils new phase of genographic project
9. King Richard III search in new phase after discovery has potential to rewrite history
10. Center for Clinical and Translational Science awards new pilot grants
11. Elseviers Maturitas publishes clinical guide on endometrial assessment in postmenopausal women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/7/2014)... Auguste, associate professor, biomedical engineering, in the Grove ... New York, have identified a molecule that could ... most aggressive forms of breast cancer. , Triple ... rate owing to aggressive proliferation and metastasis and ... Auguste,s team, discovered the overexpression of intercellular adhesion ...
(Date:11/6/2014)... A groundbreaking paper from a team of Florida State ... how plants could adapt to and survive environmental swings ... in the latest issue of the journal The ... complex of DNA and proteins) is organized in a ... some genes are turned on and others are turned ...
(Date:11/6/2014)... Baltimore, MD, November 6, 2014 - Insilico Medicine, ... in aging and age related diseases announced a ... medicine of cancer, Champions Oncology, Inc (OTC: CSBR). ... genomics for personalized medicine, but Champions Oncology,s TumorGraft ... can validate the chemotherapy regimen experimentally generating vast ...
Breaking Biology News(10 mins):Maize analysis yields whole new world of genetic science 2Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2
... Academic Affairs John Wiecha, MD, MPH, in the Department ... Health (NIH) American Recovery & Reinvestment Act (ARRA) Challenge ... valued at more than $950,000 will fund a study ... diabetes. The health education will be conducted either ...
... years ago, vertebrates lacked the ability to chew their food. ... a flexible, fused basket of cartilage. This week, an ... the University of Colorado at Boulder published evidence that three ... development of jaws in higher vertebrates. The finding is ...
... adverts, the secret of fertility might not be eternal youth. ... Research at the Consejo Superior de Investigaciones Cientficas in Seville, ... have evolved to protect their seeds. His research is published ... Botany ( http://dx.doi.org/10.1093/aob/mcq160 ). Prof. Herrera said: "No ...
Cached Biology News:Wiecha receives grant to study face-to-face vs. virtual health education for African-American women 2Genetic clues to evolution of jaws in vertebrates unearthed by CU-led team 2
(Date:11/24/2014)... Calif. , Nov. 24, 2014   Veracyte, Inc. ... Bonnie H. Anderson , president and chief executive officer, will ... 26 th Annual Healthcare Conference on Tuesday, December 2, ... . The live audio webcast and subsequent ... http://investor.veracyte.com . Please connect to the website at least 15 ...
(Date:11/24/2014)... Dallas, Texas (PRWEB) November 24, 2014 ... China Adipic Dihydrazide Industry is a professional and ... It provides Adipic Dihydrazide information, like its definition, ... as industry overview. This report covers the international ... as global (such as the US, Europe, Asia, ...
(Date:11/24/2014)... PHILADELPHIA , November 24, 2014 ... Reference Workflow, honored for dynamic leadership skills, business acumen ... scientific, technical and medical information products and services, congratulates ... Manager for Clinical Reference and Workflow, Elsevier Clinical Solutions, ... Women Worth Watching ® Awards issue of ...
(Date:11/22/2014)... 21, 2014 During his lifetime Richard ... need to surround himself with great people and take ... his friends often marveled at his extraordinarily courageous attitude ... life and -- even with his death impending—that’s how ... disease that would ultimately take his life. , Carrying ...
Breaking Biology Technology:Veracyte to Present at the Piper Jaffray 26th Annual Healthcare Conference 2Adipic Dihydrazide Industry 2019 Research Forecasts on Worldwide, China Regions Now Available at ReportsnReports.com 2Adipic Dihydrazide Industry 2019 Research Forecasts on Worldwide, China Regions Now Available at ReportsnReports.com 3Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 2Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 3Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3
... 2009A team of Los Alamos researchers led by Victor ... multiple electronsis a real phenomenon in tiny semiconductor crystals ... that mimic carrier multiplication. The research, explained in a ... shows the possibility of solar cells that create more ...
... Personalized Medicine Conference is bringing together the wide variety of stakeholders ... opportunities and challenges facing those involved in the development and realization ... ... 10, 2009 -- Arrowhead,s 2009 Personalized Medicine Conference is ...
... System Will Continue to Fuel Growth and Generate CashNEW YORK, ... Vice President James C. Borel said today he expects DuPont ... share by at least 1 to 2 points in 2009 ... DuPont Agriculture & Nutrition segment an average of at least ...
Cached Biology Technology:Research highlights potential for improved solar cells 2Research highlights potential for improved solar cells 3The Biggest Names in the Field of Personalized Medicine to Speak at Arrowhead's Upcoming 2009 Personalized Medicine Conference 2The Biggest Names in the Field of Personalized Medicine to Speak at Arrowhead's Upcoming 2009 Personalized Medicine Conference 3DuPont Expects Increased Global Seed Corn Share, Continued Agriculture Earnings Growth 2DuPont Expects Increased Global Seed Corn Share, Continued Agriculture Earnings Growth 3DuPont Expects Increased Global Seed Corn Share, Continued Agriculture Earnings Growth 4DuPont Expects Increased Global Seed Corn Share, Continued Agriculture Earnings Growth 5
... high current power supply capable of producing up ... an excellent choice for PAGE, SDS-PAGE and DNA ... for all types of electroblotting applications.A dual function ... a run and wil automatically accrue elapsed time ...
... use in Refrigerated Vapor Trap Models RVT100, ... (UVS) Models UVS400, UVS400A and UVS800DDA., A ... for use for temperatures ranging from -105 ... thermal stability and does not evaporate. Far ...
... of proteomics demands the detection of very ... of the AXIMA-CFRplus with improved resolution (20,000) ... provides increased confidence in protein identification. The ... sensitivity, automated sample target handling and the ...
... the Axima range, the AXIMA-CFR provides ... resolution, sensitivity and mass range, and ... and reflectron time-of-flight analysis. The unique ... generation of seamless PSD, providing efficient ...
Biology Products: